Frost & Sullivan: The global ADC drug market is growing at a rapid pace, presenting Chinese innovative pharmaceutical companies with opportunities for differentiated competition

Compared to the global ADC clinical research targets, domestic pharmaceutical companies' target landscape in the ADC drug field is relatively concentrated. Popular research targets include well-established targets such as HER2, TROP2, EGFR, and CLDN-18.2. Domestic pharmaceutical companies usually adopt methods such as optimizing drug design and differentiated indications to find breakthroughs in the fierce competition. At the same time, since targets are an important innovation area of ADC drugs, with the development and progress of multi-omics technology in recent years, domestic enterprises have continuously made breakthroughs and innovations in the ADC drug research and development field through the layout of new targets. Currently, the target selection of ADC drugs has expanded from traditional antigens expressed on the surface of tumor cells to the tumor microenvironment, showing potential for developing new ADC drugs.

The inclusion of vedotuzumab and trastuzumab in medical insurance not only reduces the economic burden on patients and benefits a large number of domestic patients but also marks an important progress in the market access of ADC drugs in China, which will further drive the development of the domestic ADC drug market. According to Frost & Sullivan's data analysis, the global ADC drug market size has always maintained high-speed growth, increasing from $2 billion in 2018 to $10.4 billion in 2023, with a compound annual growth rate of 39.1%; it will continue to grow at a compound annual growth rate of 30.3% from 2023 to 2030, and it is expected that the global ADC drug market size will grow to $662 billion by 2030.

ADC drugs have revolutionized the treatment paradigm of cancer, bringing huge market opportunities. While attracting a large number of innovative pharmaceutical companies and capital, they also test the R&D innovation, clinical design, strategic execution, and commercialization capabilities of major pharmaceutical companies. Innovation is the driving force for breakthroughs in ADC drugs. Although the design concept of ADC drugs seems simple, due to its three-part combination, the complex and variable components make the R&D innovation of ADCs more challenging for pharmaceutical companies' combined innovation capabilities. At the same time, the ultimate manifestation of the innovative value of ADC drugs is in clinical results. One of the important factors for the successful development of ADC drugs lies in establishing effective clinical trials and treatment plans. In addition, commercial production is the key point for the transformation of ADC drug innovation achievements. From drug discovery to the commercial development of a single ADC product, it usually requires a large amount of continuous capital investment, ranging from hundreds of millions to over a billion dollars. Therefore, enterprises with comprehensive competitive advantages in the above three aspects or those that can form cooperative advantages and complement each other in these aspects are expected to stand out in the fierce competition of ADC drug development.